This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.64% per year. These returns cover a period from January 1, 1988 through August 4, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Wall Street Analysts Think Kiniksa Pharmaceuticals, Ltd. (KNSA) Could Surge 100%: Read This Before Placing a Bet
by Zacks Equity Research
The average of price targets set by Wall Street analysts indicates a potential upside of 100.2% in Kiniksa Pharmaceuticals, Ltd. (KNSA). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.
Kiniksa Pharmaceuticals, Ltd. (KNSA) Reports Q3 Loss, Tops Revenue Estimates
by Zacks Equity Research
Kiniksa Pharmaceuticals, Ltd. (KNSA) delivered earnings and revenue surprises of 30.16% and 21.93%, respectively, for the quarter ended September 2021. Do the numbers hold clues to what lies ahead for the stock?
Kiniksa Pharmaceuticals, Ltd. (KNSA) Reports Q2 Loss, Tops Revenue Estimates
by Zacks Equity Research
Kiniksa Pharmaceuticals, Ltd. (KNSA) delivered earnings and revenue surprises of 11.59% and 200.94%, respectively, for the quarter ended June 2021. Do the numbers hold clues to what lies ahead for the stock?
Arena (ARNA) Q1 Earnings Beat Estimates, Etrasimod Progresses
by Zacks Equity Research
Arena Pharmaceuticals (ARNA) beats Q1 bottom-line estimates. The company progresses with the development of its key pipeline candidate, etrasimod.
New Strong Sell Stocks for January 27th
by Zacks Equity Research
Here are 5 stocks added to the Zacks Rank #5 (Strong Sell) List today.
Company News for Oct 7, 2020
by Zacks Equity Research
Companies in the news are: KNSA, GMDA, BNTX, NAKD
Zacks.com featured highlights include: eXp World, Lakeland Industries, Meridian Bioscience, Kiniksa Pharmaceuticals and iClick Interactive Asia Group
by Zacks Equity Research
Zacks.com featured highlights include: eXp World, Lakeland Industries, Meridian Bioscience, Kiniksa Pharmaceuticals and iClick Interactive Asia Group
Company News for Jun 30, 2020
by Zacks Equity Research
Companies in the news are: KNSA, TLSA, COTY, ICPT
5 Stocks With Recent Price Strength Amid Spike in Coronavirus
by Nalak Das
Investors target stocks that are witnessing a bullish run. Actually, stocks seeing price strength have a high chance of carrying the momentum forward.
Zacks.com featured highlights include: SunOpta, eXp World, Calix, Kiniksa Pharmaceuticals and iClick Interactive Asia Group
by Zacks Equity Research
Zacks.com featured highlights include: SunOpta, eXp World, Calix, Kiniksa Pharmaceuticals and iClick Interactive Asia Group
5 Stocks With Recent Price Strength on Upbeat Economic Data
by Nalak Das
Investors target stocks that are witnessing a bullish run. Actually, stocks seeing price strength have a high chance of carrying the momentum forward.
How Kiniksa Pharmaceuticals (KNSA) Stock Stands Out in a Strong Industry
by Zacks Equity Research
Kiniksa Pharmaceuticals (KNSA) has seen solid earnings estimate revision activity over the past month, and belongs to a strong industry as well.
Will Kiniksa Pharmaceuticals Continue to Surge Higher?
by Zacks Equity Research
As of late, it has definitely been a great time to be an investor Kiniksa Pharmaceuticals
New Strong Buy Stocks for May 1st
by Nitish Marwah
Here are 5 stocks added to the Zacks Rank #1 (Strong Buy) List today.
Has Kiniksa Pharmaceuticals (KNSA) Outpaced Other Medical Stocks This Year?
by Zacks Equity Research
Is (KNSA) Outperforming Other Medical Stocks This Year?
Company News for Apr 1, 2020
by Zacks Equity Research
Companies In The News Are: KNSA, EYEG, VBIV, EYES
Gilead's BLA for CAR T Cell Therapy Gets FDA Acceptance
by Zacks Equity Research
The FDA accepts Gilead's (GILD) BLA for its second CAR T cell therapy, KTE-X19.
Gilead (GILD) Q4 Earnings Miss Estimates, Revenues Beat
by Zacks Equity Research
Gilead's (GILD) earnings fall short of estimates but sales beat the same in the fourth quarter of 2019.
The Zacks Analyst Blog Highlights: Amarin, Amgen, Gilead Sciences, Biogen and Kiniksa Pharmaceuticals
by Zacks Equity Research
The Zacks Analyst Blog Highlights: Amarin, Amgen, Gilead Sciences, Biogen and Kiniksa Pharmaceuticals
Biotech Stock Roundup: AMRN Stock Up, Pipeline Updates from GILD, BIIB, AMGN & More
by Zacks Equity Research
The biotech sector was in focus this week with pipeline and regulatory updates from quite a few players.
Gilead Teams Up With Kiniksa, Submits BLA for CAR T Therapy
by Zacks Equity Research
Gilead (GILD) collaborates with Kiniksa for a combination study and submits BLA for CAR T therapy candidate.
Company News For Nov 21, 2019
by Zacks Equity Research
Companies in the news are: URBN, KNSA, ACB, ENDP
Kiniksa Pharmaceuticals Enters Oversold Territory
by Zacks Equity Research
Kiniksa Pharmaceuticals, Ltd. (KNSA) has been on a bit of a cold streak lately, but there might be light at the end of the tunnel for this overlooked stock.
5 Best-Performing IPOs of 2018
by Nitish Marwah
Strong economic fundamentals and increased foreign investment have led to such a high number of companies going public.